Scientific paper
Is resection appropriate for adenocarcinoma of the pancreas?: A cost-benefit analysis

https://doi.org/10.1016/0002-9610(87)90236-4Get rights and content

Abstract

Our data support the contention that biliary bypass combined with gastric bypass is the treatment of choice for the majority of patients with adenocarcinoma of the pancreas. Compared with resection, operative morbidity and mortality rates were lower, length of hospitalization was shorter, and the cost of treatment was lower. There was no significant difference in survival.

In choosing candidates for resection, the surgeon must balance the meager chances for cure (less than 1 percent) with the considerable operative hazard and the risk of lethal, costly complications. In our view, resection should be considered only for physiologically young patients with small localized lesions. These patients should be referred to surgeons specializing in pancreatic surgery who have had operative mortality rates of less than 10 percent. Pancreatic resection must, therefore, be deprived of its appeal as a procedure to which every surgeon must aspire.

References (13)

There are more references available in the full text version of this article.

Cited by (50)

  • Assessment of health care cost for complex surgical patients: Review of cost, re-imbursement and revenue involved in pancreatic surgery at a high-volume academic medical centre

    2015, HPB
    Citation Excerpt :

    Most of the earlier reports, investigating the expenses related to pancreatic surgery, report charges. However, this is an inaccurate representation of hospital financials, because charges do not reflect actual costs and can significantly vary between institutions.9,10 Current literature provides information on total costs associated with pancreatic surgery;11-13 however, there is sparse data showing the cost breakdown and even fewer data on reimbursement and revenue.

  • Pancreatic cancer: The bigger picture

    2001, Surgical Clinics of North America
    Citation Excerpt :

    The best overall survival rate in a surgical series was 3.6% and, for a nonsurgical study, 1.7%. Although there is no theoretic price for a human life, the limited health care dollar and the emergence of health maintenance organizations force these decisions daily.40,56 No clues have been forthcoming from epidemiologic studies to facilitate the early diagnosis of pancreatic cancer.

View all citing articles on Scopus

Presented at the 39th Annual Meeting of the Southwestern Surgical Congress, Coronado, California, April 26–29, 1987.

1

From the Department of Surgery, St. Joseph Hospital, Denver, Colorado.

View full text